Director, Search & Evaluation
About this opportunity
- Contribute to sourcing of M&A, and BD&L deals originating in China that are aligned with global S&G priorities. - Leverage innovation in China by identifying technologies and assets in alignment with global search priorities. Present opportunities within the global S&E team and broader C&BD team. - Being the face of Novartis and the first point of contact in the region for biotechs with technologies and early-stage assets of potential interests.- Contribute to building competitive landscape reports for companies in the region. - Work as a lead for screening opportunities in China scouting for innovative technology while supporting materially sized, late-stage commercial deals.
Your responsibilities include, but are not limited to the following:Deliver against the S&G organization’s Business Development & Licensing strategies and plans/objectives.Lead the execution of finding activities and alignment with strategic priority targets.undefinedManage stakeholders, present to internal leadership teams and drive internal consensus on opportunities.Support the formal governance process to seek and obtain approval for appropriate deal opportunities and adhere to internal BD&L review process to ensure quality and consistency of the evaluation of all BD&L activities in accordance with process guidelines.Present the opportunity to appropriate deal committee and provide local support for timely negotiation and execution mandates.Foster collaboration throughout Novartis China organization to align regional commercial interests.Reporting of technical complaints / adverse events / special case scenarios related to Novartis products within 24 hours of receipt.Role RequirementsMaster’s degree in a related scientific field required. Doctorate degree is preferred, MBA, Overseas education a strong plus.5+ years of business development work experience in the pharmaceutical or biotechnology industries required; Cross-border licensing experience a strong plus.l Strong work ethic, problem-solving, and project management skills.l Strong accountability, integrity, and communication skills, with ability to appropriately represent the S&E organization internally, as well as to represent Novartis across the life sciences and finance/VC community in China and beyond.l Ability to learn fast, adapt in multi-faceted environment, and drive initiatives beyond past experiences.l Strong collaboration mindset and ability to influence without authority.l Excellent English and Mandarin.
Job details
How this role compares
Computed from every other active BD&L & Strategic Planning role in our database, not just this employer's listings.
We currently track 21 comparable Director BD&L & Strategic Planning roles across 11 biopharma companies.
Salary context
6 of 21 peers report a salary range (USD, annualized)
Peers share this role's job function and a matching or adjacent seniority level -- not necessarily the same therapeutic area or country.
Where these roles are based
Top locations among the 21 comparable roles
Seniority mix
21 of 21 peers have a known seniority level
Therapeutic area mix
4 of 21 peers have a known therapeutic area; the rest are genuinely unlabeled, not hidden
Similar opportunities
The closest matches from our peer group, ranked by how similar they are, not how well you'd qualify for them -- treat this as market context, not a guaranteed shortlist; a weak match is labeled as one below.
How we calculate "similar"
No black box, no LLM guesswork: a deterministic score built from four normalized attributes. Here's this role's own peer group at different match levels, so you can see the mechanism, not just the result.
Every comparison starts from the same 100-point budget: 25 for working in the same function, 40 for the same therapeutic area, 20 for the same or adjacent seniority, 15 for the same country. A dimension we can't confirm on both sides contributes nothing, never a guess, never a free pass.
0 points, never a partial guess. A role we know almost nothing about beyond its function bottoms out at 25%; it never inflates to 100% just because there's little to compare against. Seniority uses a defined ladder (Associate → Manager → Associate Director → Senior → Principal → Director → Senior Director → Executive/VP) so "Director" and "Senior Director" count as adjacent, but "Director" and "Executive/VP" do not.